Trial Profile

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idecabtagene vicleucel (Primary)
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms KarMMa
Sponsors Celgene Corporation

Most Recent Events

18 Sep 2025 According to Bluebird bio media release, Bluebird bio has changed its name to Genetix Biotherapeutics.
31 Jan 2024 Status changed from active, no longer recruiting to completed.
19 Aug 2023 Results of Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in this study , published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com